Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02660736
• Other study ID #: 201287
• Status: Completed
• Phase: Phase 1
• First received: January 11, 2016
• Last updated: November 8, 2016
• Start date: February 2016
• Est. completion date: August 2016

Study information

• Verified date: November 2016
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Albiglutide (Alb) is a novel analogue of glucagon-like peptide-1 (GLP-1) has been developed and approved for the treatment of type 2 diabetes mellitus. Currently, lyophilized albiglutide and the diluent are provided in a dual chamber Cartridge (DCC) single-dose pen injector, requiring reconstitution prior to use. A liquid formulation of albiglutide will enable the use of a liquid product in a ready-to-use single dose auto-injector. To support the development of the liquid auto-injector product, this healthy volunteer bioequivalence study will be conducted to compare the liquid drug product to the currently available lyophilized product. This is Phase I, randomized, double-blind, double dummy, single-dose, 2-period crossover study in healthy volunteers. This study will compare the pharmacokinetics and safety of the albiglutide 50 mg liquid drug product with the albiglutide 50 mg commercial lyophilized drug product.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Between 18 and 65 years of age.

• Healthy.

• Subject is a nonsmoker.

• Subject's body mass index (BMI) is >=18 kilogram/meter square (kg/m^2) and <=30 kg/m^2

• Male or

• Female

Exclusion Criteria:

• Alanine aminotransferase (ALT) >1.5 x upper limit of normal range (ULN)

• Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent [%]).

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities

• QT interval corrected for heart rate according to Fridericia's formula (QTcF) > 450 millisecond (msec).

• Systolic blood pressure is >=140 millimeter of mercury (mmHg) at Screening;

• Diastolic blood pressure is >=90 mmHg at Screening;

• Heart rate is >100 beats/min at Screening.

• estimated glomerular filtration rate (eGFR) <=80 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) at Screening.

• Fasting triglyceride level >300 milligram per deciliter (mg/dL) at Screening.

• History of significant cardiovascular or pulmonary dysfunction prior to Screening.

• History of thyroid dysfunction or an abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at Screening.

• History of gastrointestinal surgery that could influence gastric emptying (e.g., gastrectomy, gastric bypass).

• History of pancreatitis.

• Personal or family history of multiple endocrine neoplasia type 2.

• Personal or family history of medullary carcinoma of the thyroid.

• Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days.

• History of regular alcohol consumption within 6 months of the study.

• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.

• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.

• Subject has previously received any GLP-1 mimetic compound (eg., exenatide, liraglutide, lixisenatide, dulaglutide).

• Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.

• A positive pre-study drug/alcohol screen.

• A positive test for human immunodeficiency virus (HIV) antibody.

• Subject has donated blood in excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study.

• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Albiglutide Liquid Auto-injector
Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
• Albiglutide Lyophilized DCC Pen Injector
Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
• Placebo Liquid Auto-injector
Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
• Placebo Lyophilized DCC Pen injector
Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration-time curve (AUC) from 0 to the last measurable concentration (AUC 0-t) for albiglutide in session 1 and 2	PK blood samples will be collected for determination of albiglutide plasma concentrations and (AUC 0-t).	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2	No
Primary	AUC from 0 to infinity (AUC [0-inf]) for albiglutide in session 1 and 2	PK blood samples will be collected for determination of albiglutide plasma concentrations AUC(0-inf).	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2	No
Primary	Peak plasma concentration (Cmax) for albiglutide in session 1 and 2	PK blood samples will be collected for determination of albiglutide Cmax.	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2	No
Secondary	Time to maximal concentration (Tmax) for albiglutide in session 1 and 2	PK blood samples will be collected for determination of albiglutide Tmax.	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2	No
Secondary	Clearance (CL/F) for albiglutide in session 1 and 2.	PK blood samples will be collected for determination of albiglutide CL/F	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2	No
Secondary	Volume of distribution (V/F) for albiglutide in session 1 and 2	PK blood samples will be collected for determination of albiglutide V/F	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2	No
Secondary	Number of subjects with adverse events (AE) and clinical observations as a measure of safety and tolerability	AE will be collected during the study. Intensity of AE will be captured	Up to 21 weeks	No
Secondary	Safety as assessed by 12-lead electrocardiogram (ECG)	Single 12-lead ECGs will be obtained at the specified time points during the study using an ECG machine that automatically calculates the heart rate and other measures.	Screening, Day -1, Day 4, and Day 35 in both sessions 1 and 2	No
Secondary	Safety as assessed by systolic, diastolic blood pressure, and pulse rate measurements	Systolic and diastolic pressure and pulse rate will be measured at specified time point	Up to 21 weeks	No
Secondary	Immunogenicity as assessed by enzyme-linked immunosorbent assay (ELISA) and hypersensitivity reactions.	Immunogenicity serum samples will be collected at specified time points to assess the presence of anti-drug antibodies through enzyme-linked immunosorbent assay (ELISA) method.	Day 1 in both sessions and Day 13 in session 1 and follow-up visit	No
Secondary	Half-life (T1/2) for albiglutide in session 1 and 2	PK blood samples will be collected for determination of albiglutide T1/2.	Predose (0), 24, 48, 72, 96, 120, 216, 312, 480, 672, and 840 hours post-dose in both sessions 1 and 2.	No
Secondary	Composite of hematology parameters as a measure of safety	The following hematology parameters will be measured: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, Reticulocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), MCH Concentration, white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils.	Up to 21 weeks	No
Secondary	Composite of clinical chemistry parameters as a measure of safety	The following clinical chemistry parameters will be measured: blood urea nitrogen (BUN), creatinine, fasting glucose, uric acid, thyroid-stimulating hormone (TSH), potassium, sodium, calcium, phosphorus, magnesium, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, gamma glutamyl transferase (GGT), chloride, total and direct bilirubin, total protein, albumin, total carbon dioxide, and fasting triglycerides.	Up to 21 weeks	No
Secondary	Composite of urinalysis parameters as a measure of safety	The following urinalysis parameters will be measured: specific gravity, power of hydrogen (pH), glucose, protein, blood and ketones by dipstick; microscopic examination (if blood or protein is abnormal), microalbumin, creatinine, albumin/creatinine ratio, blood, leukocyte esterase, and nitrites.	Up to 21 Weeks	No